ArticleEuropean journal of pediatrics2026
Perioperative use of levosimendan in complex congenital heart disease management.
Article in European journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study evaluated the impact of perioperative levosimendan on in-hospital outcomes in children undergoing surgery for complex congenital heart disease. A retrospective cohort of 120 neonates and infants undergoing Norwood operation, arterial switch operation, or truncus arteriosus repair was analyzed. Median age at surgery was 29.5 days, and median weight was 4.0 kg. In-hospital mortality was higher in female patients, who exhibited a 2.64-fold greater mortality rate compared with males (33.3% vs. 12.6%). Levosimendan use was not significantly associated with a significant reduction in in-hospital mortality (aOR 0.76; 95% CI 0.07-1.46), major complications (aOR 0.87; 95% CI 0.44-1.30), or length of stay (aOR 0.76; 95% CI 0.36-1.16). However, treatment allocation was clinically based, introducing selection bias and confounding by indication, therefore still leaving the question of potential levosimendan efficacy in the CHD postoperative context unanswered. Thus, further studies are warranted.
conclusionIn this retrospective cohort of high-risk pediatric patients undergoing complex congenital heart surgery, perioperative levosimendan was not associated with significant differences in in-hospital mortality, postoperative length of stay, or major complications. WHAT IS KNOWN: • Vasoactive support is central after complex pediatric cardiac surgery; levosimendan is a calcium-sensitizer/inodilator used perioperatively. • Pediatric evidence is mixed: some reports suggest fewer LCOS events, but no consistent reduction in in-hospital mortality, AKI, ventilation duration, or LOS. WHAT IS NEW: • In a national referral cohort from a middle-income country, perioperative levosimendan showed no significant difference in mortality, LOS, or major complications versus no levosimendan in complex congenital heart surgery (Norwood procedure, Arterial switch operation and truncus arteriosus repair). • Among postoperative ECMO patients, LOS was numerically shorter with levosimendan but not statistically significant (exploratory).
Indexed as
Identifiers
41575556What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.